Introduction
Within the BM microenvironment, MSCs represent the precursor cells for stromal tissues that support hematopoiesis.
1,2 For many years, MSCs have been considered merely a component of marrow stroma, without any special function, and endowed only with structural support properties. Subsequently, it was shown that MSCs give a substantial contribution to the creation of the hematopoietic stem cell (HSC) niche, and have a crucial role in the development and differentiation of the lympho-hematopoietic system through cell-to-cell interactions and by secreting a number of growth factors and regulatory cytokines.
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MSC surface markers
Little is known about the characteristics of the primary mesenchymal precursors in vivo, as, so far, it has been difficult to isolate the most primitive mesenchymal cell from bulk cultures. One of the main hurdles refers to the inability to prospectively isolate MSCs because of their low frequency and the lack of specific markers. To date, MSC isolation/identification has mainly relied on their morphology and adherence to plastic; immunophenotyping by flow cytometry has been applied to identify ex vivo expanded MSCs and to define their purity. No specific marker has been shown to specifically identify true MSCs and ex vivo expanded cells are characterized by a combination of both positive (CD105, CD73, CD90, human leukocyte antigen class I) and negative (CD34, CD45, CD14, CD31) markers. 6, 7 Recently, the identification and prospective isolation of mesenchymal progenitors, both in murine and human adult BM, have been reported, based on the expression of specific markers. [8] [9] [10] [11] [12] [13] [14] Whether culture-expanded MSCs differ from their progenitors in vivo is uncertain, as proliferation on plastic surfaces and culture conditions may induce both phenotypic and functional changes. Anjos-Afonso et al. 8 have reported the identification, isolation and characterization of a population of multipotent mesenchymal cells in murine BM, based on the expression of the stage-specific embryonic antigen-1. Surface markers such as stage-specific embryonic Ag-4, STRO-1 and the low-affinity nerve growth factor receptor (CD271) have been employed with the aim to prospectively isolate human MSCs.
9-11 Battula et al. 12 have recently identified novel MSC subsets with distinct phenotypic and functional properties in human BM by using antibodies directed against the surface Ags CD271, mesenchymal stem cell Ag-1 and CD56. In particular, CD271 has been reported to define a subset of MSCs with immunosuppressive and lymphohematopoietic engraftment-promoting properties in vivo. 13 Plateletderived growth factor receptor-b (CD140b) has been also identified as a selective marker for the isolation of clonogenic MSCs; 11 an STRO-4 MoAb has been shown to be specific for mesenchymal precursors cells from human and ovine tissues, being capable of enriching colonyforming fibroblasts when employed for MSC isolation from BM. 14 Despite the identification of these new MSC markers, [8] [9] [10] [11] [12] [13] [14] none of the available reagents has been shown to be singularly capable of identifying the true mesenchymal progenitors. Future research should include the identification of MSC-specific markers, which will hopefully allow one to dissect the developmental hierarchy of MSCs and will facilitate the generation of homogeneous cellular products.
MSC ex vivo expansion
Owing to the low frequency of mesenchymal progenitors in human tissues, in vivo use of MSCs requires that the cells be extensively manipulated ex vivo to achieve the numbers that are necessary for their clinical application. [15] [16] [17] Standard conditions for ex vivo expansion of MSCs are based on the presence of 10% FCS and serum batches are routinely prescreened to guarantee both the optimal growth of MSCs and the bio-safety of the cellular product. [15] [16] [17] However, the use of FCS raises concerns when utilized in clinical grade preparations, because it might theoretically be responsible for the transmission of zoonoses or cause immune reactions in the host, especially if repeated infusions are needed, leading to the risk of consequent rejection of the transplanted cells. 18, 19 In this regard, Horwitz et al. 19 reported sensitization in a child with Osteogenesis Imperfecta treated with repeated infusions of MSCs. This sensitization was characterized by the formation of alloantibodies directed against ex vivo expanded allogeneic MSCs and was responsible for their rejection, already after their second infusion. In view of these considerations, serum-free media, appropriate for extensive expansion and devoid of the risks connected with the use of animal products, are being developed. Both autologous and allogeneic human sera have been tested for the in vitro expansion of MSCs; 20 several serumfree media, based on the use of cytokines and growth factors, such as basic fibroblast growth factor and transforming growth factor-b, have been proposed in experimental conditions. 21, 22 Platelet lysate has been shown to be a powerful substitute for FCS in MSC expansion owing to its high concentration of natural growth factors. [23] [24] [25] Doucet et al. 23 first showed that the growth factors contained in platelet lysate are capable of promoting MSC expansion in a dose-dependent manner. This was further substantiated by the data published by our and other groups, showing that a culture medium added with 5% platelet lysate is superior to 10% FCS in terms of clonogenic efficiency and proliferative capacity of MSCs. 24, 25 These results provide the rationale for a more efficient expansion together with a significant time saving, while preserving MSC immunomodulatory functions. 24, 25 However, clinical data on the safety and efficacy of MSCs have been obtained, so far, mainly with cells expanded in the presence of FCS, whereas relatively little in vivo experience is available with MSCs cultured in alternative medium supplements. Therefore, cells expanded in the presence of alternative expansion media require extensive experimental and clinical testing before being safely and effectively employed to substitute cells generated in the presence of FCS-based media.
Immunomodulatory properties of MSCs
MSCs possess broad immunomodulatory properties that make them capable of influencing, both in vitro and in vivo, the function of all cells involved in the immune response. [26] [27] [28] Human MSCs suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli; moreover, they do not stimulate T-cell proliferation in MLR. 29 MSCs are capable of inhibiting the maturation of monocytes into DCs, and of skewing mature DCs to an immature DC state. 21, 30, 31 Although resting natural killer cells stimulated with either IL-2 or IL-15 in the presence of MSCs show markedly reduced proliferation and IFN-g production, both allogeneic and autologous cytokine-activated natural killer cells can effectively kill MSCs via NKG2D. 32 Whether MSCs inhibit in vitro B-cell proliferation and differentiation, or support their survival and functions, is still a matter of discussion; 33, 34 nevertheless, as T cells orchestrate B-cell function, it is likely that the ultimate effect of MSCs on B cells is influenced in vivo by MSC inhibition on T cells.
The exact mechanisms by which MSCs exert their immunomodulatory functions, via cell-to-cell contact and/or paracrine signaling, are still poorly understood and the data available are largely restricted to in vitro studies. The in vivo significance and biological relevance of the in vitro observations needs to be clearly elucidated.
In vivo animal models to test the engraftment-promoting properties of MSCs
In vivo animal models The immunomodulatory and engraftment-promoting properties of MSCs have been tested in a variety of animal models (see Table 1 ). Indeed, MSCs have been reported to secrete cytokines important for hematopoiesis and to promote engraftment of hematopoietic cells (HCs) in experimental animal models, especially when the dose of transplanted HCs was low. 35, 36 Reasoning on the engraftment-promoting effect of MSCs in the context of hematopoietic cell transplant (HCT), it has to be highlighted that it can differ for what concerns recovery of myeloid cells, thrombocytes and lymphoid cells.
Systemic infusion of allogeneic BM-derived MSCs from baboons has been shown to suppress lymphocyte proliferation and prolong the survival of allogeneic skin grafts, as compared with animals not receiving MSCs. 37 Almeida-Porada et al. 35 observed that co-transplantation of human MSCs into pre-immune fetal sheep resulted in the enhancement of long-term engraftment of human cells in the BM and in higher levels of donor cells in the circulation both during gestation and after birth. Another study performed in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice showed that co-infusion of fetal lung-derived MSCs and cord blood-derived CD34 þ cells is associated with enhancement of engraftment of human HCs in the BM of the animals. 36 The engraftmentpromoting effect of MSCs was particularly prominent when relatively low doses of HCs were transplanted and was not lineage specific, as it was evident in both myeloid and lymphoid cells. In NOD/SCID mice, co-transplantation of placenta-derived MSCs resulted in enhanced engraftment of double umbilical cord blood transplantation (UCBT) and reduced single cord predominance. 38 In non-human primates, co-transplantation of MSCs improved HC engraftment after autologous intra-BM transplantation and this was associated with increased chimerism in the peripheral blood. 39 As already mentioned above, Kuci et al. 13 showed that CD271 þ MSCs were capable of promoting significantly greater lymphoid engraftment, as compared to an unselected population of plastic-adherent MSCs, when co-transplanted with CD133 þ HCs in NOD/SCID mice.
MSC mechanisms of action
Although for years MSCs have been considered to be cells that could be potentially ignored by the immune system, it has been more recently shown that allogeneic MSCs are not intrinsically immunoprivileged, as, under appropriate conditions, they can induce an immune response, resulting in their rejection when infused into major histocompatibility complex-mismatched mice. 40 On the contrary, the infusion of syngeneic host-derived MSCs resulted, in the same model, in enhanced engraftment of allogeneic HCs. 40 These observations suggest that MSCs may promote engraftment, provided that they survive in vivo and are not rejected as the result of an allo-immune response.
Whether the enhancement of HC engraftment, when present, is dependent of the homing of MSCs to the BM or is mediated by the release of cytokines that promote either the homing or proliferation of HCs is still unclear. Devine et al. 41 showed by gene marking that MSCs are capable of homing to the BM of non-human primates following systemic administration and that they can be detected over 1 year after infusion. In rats, radiolabeling experiments showed localization of MSCs, after intra-arterial and i.v. infusion, mostly in the lungs and, secondarily, in the liver and other organs. 42 Other authors have shown that active homing of MSCs into the BM depends on stromal-derived factor-1, which interacts with CXCR4 on the MSC surface. 43 Conversely, it might be possible that the engraftment-promoting effect is obtained by the secretion of paracrine growth factors produced by MSCs, which might promote the creation of a favorable microenvironment for the survival, proliferation and engraftment of HCs. In this latter case, MSC survival and sustained engraftment would not be not required for their therapeutic effect. See also Table 2 for details.
A possible strategy to facilitate homing of MSCs involves the modification of surface structures that have a role in migration to specific tissues, as suggested by Sackstein et al. 44 These authors converted the native CD44 glycoform expressed on MSCs into E-selectin/L-selectin ligand (HCELL) (expressed on HCs) using fucosyltransferase. Intravital micro- Table 2 MSC potential mechanisms that can be hypothesized to be at the basis of their capacity to enhance engraftment/accelerate hematopoietic recovery
Immunological mechanisms
Ability to suppress T-lymphocyte-mediated cytotoxicity against alloAgs Ability to induce generation/differentiation of regulatory T cells Ability to blunt NK cell-mediated alloreactivity Ability to interfere with DC differentiation, maturation and function Trafficking studies by labeling MSCs are warranted to investigate the in vivo biodistribution of MSCs both in animal models and in human beings. Efforts should focus on the development of new tracers to label MSCs and to track them in vivo, hopefully without interfering with their biological functions and without inducing toxic effects in the recipients. 45, 46 The acquisition of information on survival of MSCs in vivo and on their ability to engraft in host tissues will be of fundamental interest for acquiring knowledge on MSC biology and functions and, therefore, for advancing the field.
Non-immunological mechanisms
Clinical applications of MSCs to promote hematopoietic engraftment
Clinical trials of MSC infusion to promote engraftment
The experimental data obtained in vitro and in animal models on the immunomodulatory and engraftment-promoting properties of MSCs have generated clinical interest in their application to the field of HCT, with the scope of preventing graft failure and/or facilitating hematopoietic recovery (see Table 3 ).
The first clinical trial on the use of MSCs for accelerating hematological recovery was performed in 28 breast cancer patients given autologous transplantation of peripheral blood HCs and co-infused with 1-2 Â 10 6 MSCs per kg body weight. No MSC-related toxicity was registered, and rapid hematopoietic recovery was noted. 47 After this study, a multicenter phase I/II trial aimed at evaluating the safety of MSC infusion was conducted in 46 patients affected by hematological malignancies and receiving allogeneic HCT from an human leukocyte antigen-identical sibling. 48 MSC co-infusion was not associated with adverse events; hematopoietic recovery was prompt for most patients, as the median times to neutrophil and platelet engraftment were 14 and 20 days, respectively; moderate to severe acute GvHD was observed in 28% of the patients. In a phase I/II, multicenter clinical trail, expansion of donor-derived MSCs proved to be feasible, and their clinical use safe, in children given a T-cell-depleted human leukocyte antigen-disparate allograft from a relative. 15 All patients given MSCs showed sustained hematopoietic engraftment without any adverse reaction, as compared with 20% graft failure rate in the historical controls. The leukocyte recovery was faster in children given MSCs as compared with the historical controls (see also Table 3 ). In the setting of UCBT, MSCs have been first employed in a single patient transplanted with umbilical cord blood (UCB) cells with the aim of improving the outcome of double unit UCBT. 49 In this patient, MSCs were administered without clinical adverse effects and the single unit predominance described after multiple UCBT was not observed. In a pediatric, phase I-II clinical trial, including eight children given co-transplantation of unrelated donor UCB cells and ex vivo expanded third-party MSCs, infusion of MSCs proved to be safe and patients had a neutrophil recovery at a median time of 19 days after the allograft. 50 In another pediatric, phase I/II clinical study, the safety and efficacy of co-transplantation of parental MSCs was tested in 13 pediatric patients given UCB-derived HCs; the results were compared with those obtained in historical controls receiving UCBT alone. 16 The feasibility and safety of the approach was confirmed; however, in contrast with pre-clinical results 36 and the experience reported in the haploidentical transplants, 15 no difference was found in terms of both engraftment rate and speed of hematological recovery between the two groups, although much less study patients were given G-CSF as compared with controls. Interestingly, MSC co-infusion significantly reduced the incidence of life-threatening acute GvHD and GvHD-associated TRM, as compared with controls. 16 In adult patients receiving UCBT with coinfusion of third-party donor-mobilized HCs, MSC administration at the time of transplantation had no effect on the kinetics of UCB cell engraftment, as well as on GvHD prevention. 51 Altogether, these data indicate that co-transplantation of HCs and MSCs is safe, while there is still uncertainty about a real efficacy of MSCs on promoting engraftment of donor cells and accelerating the speed of hematological recovery. In particular, in some contexts (such as T-cell-depleted human leukocyte antigen-disparate allograft from a 35 ,41 the transplantability and sustained engraftment of MSCs in human beings are largely controversial, probably being unusual events. In fact, a number of studies have documented that marrow stroma remains of host origin after allogeneic HCT in the majority of patients, [52] [53] [54] whereas others have shown limited engraftment capacity of MSCs following HCT in both adult and pediatric patients. 19, 55, 56 Chimerism analysis of ex vivo expanded MSCs derived from recipient BM after co-infusion of MSCs and HCs, both in the haploidentical and UCBT settings, 15, 16 did not show evidence of donor cells in the majority of patients, this suggesting that sustained engraftment of MSCs occurs seldom, but might not be necessary to induce therapeutic benefit.
MSCs as a platform to expand HCs
Although apparently ineffective in promoting engraftment when co-infused in UCBT, MSCs co-cultured with UCBderived HCs were successful in their ex vivo expansion ability by generating greater numbers of total nucleated cells and hematopoietic progenitor cells, as compared with ex vivo liquid culture of CD133 þ cells. 57 In this regard, a clinical trial is underway at MD Anderson Cancer Center (Houston, Tx, USA) combining an unmanipulated UCB unit with an UCB unit expanded on a layer of BM-derived MSCs. 58 
MSC infusion and risk of immune suppression
Concerns remain over the potential systemic immunosuppression mediated by MSCs after in vivo administration. In immunocompetent mice, Djouad et al. 59 showed that local, as well as systemic infusion of MSCs, suppressed the host antitumor immune response, thus favoring allogeneic tumor formation. In human beings, data obtained in a single study enrolling a limited number of patients suggested that co-transplantation of MSCs and HCs may result in an increased risk of relapse in patients with hematological malignancy, as compared to patients receiving standard HCT. 60 On the contrary, data obtained in phase I/II clinical trials performed within the Developmental Committee of the European Group for Blood and Marrow Transplantation, from patients receiving MSCs either to promote engraftment or to treat acute GvHD, do not show an increased risk of both infection and relapse, as compared with historical controls. [15] [16] [17] Whether MSC treatment can further aggravate immune incompetence and increase the risk of infections, as well as favor relapse in patients with malignant disorders, needs to be further investigated. Interestingly, Karlsson et al. 61 performed specific analysis of EBV and CMV reactivity in two patients treated with MSCs for steroid-refractory acute GvHD and showed that effector functions of virus-specific T cells were retained after MSC infusion.
Conclusions and future directions
Thus far, MSCs have been employed in the clinical setting in phase I/II clinical trials, whose design was more able to show feasibility and safety of infusion than efficacy. 15, 16, [47] [48] [49] [50] [51] Indeed, to date no adverse effects have been registered after MSC administration, although a longer follow-up is necessary to draw definitive conclusions on potential late adverse events. The execution of large, multicenter, randomized clinical trials specifically addressing response to MSC therapy in terms of prevention of graft failure and facilitation/acceleration of hematopoietic recovery, in comparison with conventional treatment modalities, is warranted to show the real value of this approach.
Moreover, extensive in vitro and in vivo testing is required to dissect the mechanisms by which MSCs exert their immunomodulatory and engraftment promoting effects; this would broaden the understanding of the biological and functional properties of MSCs relevant for modulation of alloreactivity and promotion of hematopoietic reconstitution.
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